JorgeJulioCastilloMD
Hematology • Boston, MAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Dr. Castillo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6045Fax+1 617-582-8608- Is this information wrong?
Summary
- Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his Internal Medicine and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School and serves as the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute. Dr. Castillo is also the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 275 peer-reviewed articles and has published his research in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.
Education & Training
Brown UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Autonomous Metropolitan University XochimilcoClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2013 - 2026
NH State Medical License 2023 - 2025
RI State Medical License 2005 - 2014- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Robert A. Kyle Award International Workshop for Waldenstrom Macrolgobulinemia, 2022
- Innovation Dana-Farber Cancer Institute, 2022
Clinical Trials
- Dasatinib In Waldenström Macroglobulinemia Start of enrollment: 2019 Nov 04
Roles: Sponsor-Investigator, Contact, Principal Investigator
- Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab Start of enrollment: 2010 Jul 01
- ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy Start of enrollment: 2021 Nov 16
Roles: Contact, Sponsor-Investigator, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.Gilad Itchaki, Osnat Jarhovsky, Moshe L Gatt, Merav Leiba, Pia Raanani, Iuliana Vaxman, Jorge J Castillo, Hamza Hassan, Morie A Gertz> ;Leukemia & Lymphoma. 2024 Mar 19
- Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia.Richardson, K., Castillo, J., Sarosiek, S., Branagan, A., Flynn, C., Meid, K., Gutine, J., Liu, X., Kofides, A., Liu, S., Wolf, J., Kacena, K., Patterson, C., Guerrera...> ;Blood Advances. 2024 Jan 18
- 1 citationsHow we use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia.Steven P Treon, Shayna Sarosiek, Jorge J Castillo> ;Blood. 2024 Jan 11
- Join now to see all
Press Mentions
BTK and BCL2 Inhibitors in Waldenström MacroglobulinemiaDecember 12th, 2022
Committees
- Member, IWMF Scientific Advisory Committee 2020 - Present
- Member, NCCN (Myeloma, Waldenstrom and Amyloidosis) 2016 - Present
Professional Memberships
- Member
- Member
- European Haematology AssociationMember
- International Myeloma SocietyMember
Other Languages
- Spanish
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
